Peptide Education Manager
Edit CJC-1295 / Ipamorelin
Name
Scientific / Common Name
Alternative Names
Slug (url-safe, unique)
Short Description (shown on cards)
A two-peptide combination studied for its potential role in supporting the body's natural growth hormone release pathways.
Overview — What Is It? (paragraphs)
CJC-1295 and Ipamorelin are two separate peptides that are sometimes combined because they act on different parts of the pathway that controls growth hormone release. CJC-1295 is a growth hormone releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue that acts through ghrelin receptor signaling. Researchers have studied each peptide individually for its effects on growth hormone pulsatility, and some have explored whether combining the two produces a more pronounced effect than either alone. This combined formulation itself has less dedicated research than its individual components. As with many investigational peptides, understanding of long-term effects and optimal use in humans continues to evolve.
Why Being Studied (one item per line)
Growth hormone pathway stimulation Sleep architecture and restorative sleep Lean body composition Recovery following physical training
How It May Work
CJC-1295 is proposed to extend the half-life of growth hormone releasing hormone signaling at the pituitary, while Ipamorelin is thought to mimic ghrelin and stimulate a separate growth hormone release pathway. Together, researchers have theorized these two mechanisms may produce an additive effect on growth hormone pulses, though the combined formulation has not been studied as extensively as each peptide alone.
Mechanism Pathway Steps (one per line)
CJC-1295 + Ipamorelin Pituitary GHRH & ghrelin receptor pathways Growth hormone pulse release Downstream effects on recovery & body composition under study
Evidence Rating
Established / Approved Use
Strong Human Evidence
Moderate Human Evidence
Early Human Evidence
Preclinical Evidence
Emerging / Limited Evidence
Human Evidence
Ipamorelin and CJC-1295 individually have been studied in small human pharmacology studies examining growth hormone secretion. Human data specifically on the combined 10mg/10mg formulation is limited.
Preclinical Evidence
Animal and in-vitro research has examined receptor binding and growth hormone secretagogue activity for both components separately.
What We Don't Know Yet
Long-term safety of combined use, optimal dosing, and whether combining the two peptides provides meaningfully different outcomes than either alone in humans remain open questions.
Research Area Cards (format: Title: description — one per line)
Muscle & Body Composition: Growth hormone pathway activity has been studied in relation to lean mass and fat metabolism. Sleep: Growth hormone release is linked to deep sleep stages, an area of interest for this combination. Recovery: Researchers have explored whether growth hormone secretagogues may support post-exercise recovery.
Why Might Someone Discuss This With Their Provider?
Someone interested in longevity, recovery, or growth hormone pathway research may come across this combination while exploring secretagogue-based peptide therapies.
Regulatory Status
Neither CJC-1295 nor Ipamorelin is FDA-approved for any indication. This combined formulation is not an FDA-approved drug product.
Important Considerations
Growth hormone pathway peptides can influence blood sugar and other hormone levels. Evidence for the specific combined formulation is limited, and individual ingredient research does not automatically establish evidence for the combination. Discuss any growth hormone secretagogue with a licensed provider before considering it.
Related Peptide Slugs (one per line)
ipamorelin sermorelin tesamorelin
Is Combination Product?
Combination Ingredients (format: Name: description — one per line)
CJC-1295: A growth hormone releasing hormone (GHRH) analog studied for its potential to extend the duration of growth hormone pulses. Ipamorelin: A selective growth hormone secretagogue studied for stimulating growth hormone release through ghrelin receptor pathways.
Why Are These Combined?
CJC-1295 and Ipamorelin act on two distinct parts of the growth hormone release pathway. Researchers have explored whether pairing a GHRH analog with a ghrelin-receptor-based secretagogue produces a more pronounced pulse of growth hormone than either peptide alone. Evidence supporting an individual ingredient does not automatically establish evidence for this specific combined formulation.
Categories / Goals
Recovery & Repair
Metabolic Health
Weight Management
Performance
Muscle & Body Composition
Sleep & Recovery
Cognitive Health
Stress & Mood
Longevity & Healthy Aging
Cellular Energy
Skin, Hair & Aesthetics
Sexual Wellness
Search Tags (comma separated)
Last Reviewed Date
Display Order
Published
Featured
Save Peptide